UK Chooses mRNA Boosters For COVID-19 Vaccination Campaign
In making its recommendations for the autumn vaccination program against COVID-19, the UK’s JCVI says Novavax’s Nuvaxovid could be used in exceptional circumstances, but there is no room for AstraZeneca’s Vaxzevria.
You may also be interested in...
The mRNA-1273.214 vaccine will add to the UK’s armory for protecting people against coronavirus over the coming winter season.
The bivalent vaccine is likely to get regulatory support, along with government contracts, but competitors, notably Moderna, will also step into the ring.
From next year, more agencies will be involved in the UK’s regulatory reliance procedure for new drug approvals, which was first introduced in 2021 to allay fears of post-Brexit delays to UK applications. The pharmaceutical industry said it looked forward to working with the regulator on the new framework.